SI vs ZBH

For growth investors, SHOULDER INNOVATIONS, INC.

(SI) is the stronger pick with 64. 1% revenue growth year-over-year, versus 7. 2% for Zimmer Biomet Holdings, Inc. (ZBH). Zimmer Biomet Holdings, Inc. (ZBH) offers the better valuation at 23. 5x trailing P/E (9. 8x forward), making it the more compelling value choice. Analysts rate SHOULDER INNOVATIONS, INC. (SI) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, SHOULDER INNOVATIONS, INC.

(SI) delivered a total return of -15. 1%, compared to -47. 3% for Zimmer Biomet Holdings, Inc. (ZBH). Over 10 years, the gap is even starker: SI returned -12. 3% versus ZBH's -18. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Zimmer Biomet Holdings, Inc.

(ZBH) is the lower-risk stock at 0. 60β versus SHOULDER INNOVATIONS, INC. 's 0. 77β — meaning SI is approximately 29% more volatile than ZBH relative to the S&P 500.

By revenue growth (latest reported year), SHOULDER INNOVATIONS, INC.

(SI) is pulling ahead at 64. 1% versus 7. 2% for Zimmer Biomet Holdings, Inc. (ZBH). On earnings-per-share growth, the picture is similar: Zimmer Biomet Holdings, Inc. grew EPS -19. 9% year-over-year, compared to -22. 2% for SHOULDER INNOVATIONS, INC.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Zimmer Biomet Holdings, Inc.

(ZBH) is the more profitable company, earning 8. 6% net margin versus -49. 4% for SHOULDER INNOVATIONS, INC. — meaning it keeps 8. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ZBH leads at 16. 5% versus -46. 3% for SI. At the gross margin level — before operating expenses — SI leads at 77. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for SI: 64.

4% to $21. 00.

In this comparison, ZBH (1.

1% yield) pays a dividend. SI does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Zimmer Biomet Holdings, Inc.

(ZBH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 60), 1. 1% yield). Both have compounded well over 10 years (ZBH: -18. 8%, SI: -12. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SI is a small-cap high-growth stock; ZBH is a mid-cap quality compounder stock. ZBH pays a dividend while SI does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.